SSP084 Adipine®XL 30mg modified-release tablet
The Department of Health and Social Care (DHSC) has issued a Serious Shortage Protocol (SSP) for Nifedipine (Adipine® XL) 30mg modified-release tablets in response to a significant ongoing supply disruption.
This SSP will enable community pharmacists in England, Wales, Scotland and Northern Ireland to supply patients with a different product as per the document below.
It allows an alternative medicine from the list below to be supplied against prescriptions for Adipine® XL 30mg MR tablets.
- Nifedipine (Adanif® XL) 30mg modified-release tablet
- Nifedipine (Neozipine® XL) 30mg modified-release tablet
- Nifedipine (Coracten® XL) 30mg modified-release capsule
The total quantity supplied under this protocol should be equivalent to the number of days supplied on the original prescription.
The pharmacist must exercise their professional judgement to ensure the alternative product is suitable for the patient. Where the patient/carer is supplied with Coracten® XL modified-release capsules, the pharmacist should ensure that they is made aware that this product contains gelatine which may not be acceptable to some patients on cultural or religious grounds. Patients should be advised that they may require closer monitoring initially to ensure blood pressure/angina symptoms remain controlled, and to report any adverse effects.
SSP084 for Adipine® XL 30mg MR tablets will be in operation from Friday 19th December 2025 until Friday 6th February 2026.
Please note that the SSP may be amended or revoked at any time, so contractors must ensure that the SSP is still valid before each supply.
SSP084 for Adipine® XL 30mg MR tablets